Morgan Stanley
KYNB

Morgan Stanley’s Kyntra Bio KYNB Stock Holding History

Morgan Stanley’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.68K Sell
487
-1
-0.2% -$7 ﹤0.01% 7281
2026
Q1 		$3.31K Sell
488
-5,436
-92% -$42.5K ﹤0.01% 7233
2025
Q4 		$52K Buy
5,924
+4,378
+283% +$42.8K ﹤0.01% 6416
2025
Q3 		$18.9K Sell
1,546
-114
-7% -$1.07K ﹤0.01% 6704
2025
Q2 		$8.8K Sell
1,660
-2,250
-58% -$16.4K ﹤0.01% 6894
2025
Q1 		$30.3K Buy
3,910
+2,392
+158% +$28.7K ﹤0.01% 6436
2024
Q4 		$20.1K Sell
1,518
-151
-9% -$1.4K ﹤0.01% 6572
2024
Q3 		$16.7K Sell
1,669
-7,790
-82% -$118K ﹤0.01% 6554
2024
Q2 		$211K Sell
9,459
-5,072
-35% -$157K ﹤0.01% 5650
2024
Q1 		$854K Sell
14,531
-18,130
-56% -$781K ﹤0.01% 5055
2023
Q4 		$724K Sell
32,661
-23,299
-42% -$351K ﹤0.01% 5123
2023
Q3 		$1.21M Buy
55,960
+30,064
+116% +$1.18M ﹤0.01% 4688
2023
Q2 		$1.75M Sell
25,896
-8,434
-25% -$3.49M ﹤0.01% 4504
2023
Q1 		$16M Buy
34,330
+15,610
+83% +$8.26M ﹤0.01% 2668
2022
Q4 		$7.5M Buy
18,720
+5,107
+38% +$1.96M ﹤0.01% 3364
2022
Q3 		$4.43M Sell
13,613
-12,418
-48% -$4M ﹤0.01% 3798
2022
Q2 		$6.87M Buy
26,031
+4,514
+21% +$1.15M ﹤0.01% 3465
2022
Q1 		$6.46M Buy
21,517
+10,339
+92% +$3.6M ﹤0.01% 3397
2021
Q4 		$3.94M Sell
11,178
-2,598
-19% -$809K ﹤0.01% 3966
2021
Q3 		$3.52M Sell
13,776
-4,564
-25% -$1.62M ﹤0.01% 4075
2021
Q2 		$12.2M Sell
18,340
-3,822
-17% -$2.2M ﹤0.01% 2762
2021
Q1 		$19.2M Buy
22,162
+6,588
+42% +$7.01M ﹤0.01% 1957
2020
Q4 		$14.4M Buy
15,574
+10,699
+219% +$11.2M ﹤0.01% 2129
2020
Q3 		$5.01M Sell
4,875
-1,534
-24% -$1.65M ﹤0.01% 2712
2020
Q2 		$6.5M Sell
6,409
-243
-4% -$226K ﹤0.01% 2407
2020
Q1 		$5.78M Sell
6,652
-3,038
-31% -$3.02M ﹤0.01% 2315
2019
Q4 		$10.4M Buy
9,690
+2,896
+43% +$2.96M ﹤0.01% 2400
2019
Q3 		$6.28M Buy
6,794
+587
+9% +$645K ﹤0.01% 2628
2019
Q2 		$7.01M Sell
6,207
-9,228
-60% -$10.1M ﹤0.01% 2555
2019
Q1 		$21M Buy
15,435
+5,014
+48% +$6.8M 0.01% 1405
2018
Q4 		$12.1M Sell
10,421
-1,440
-12% -$1.62M ﹤0.01% 1924
2018
Q3 		$18M Sell
11,861
-1,847
-13% -$2.84M ﹤0.01% 1798
2018
Q2 		$21.5M Sell
13,708
-2,143
-14% -$2.79M 0.01% 1575
2018
Q1 		$18.3M Buy
15,851
+4,671
+42% +$6.15M 0.01% 1751
2017
Q4 		$13.2M Buy
11,180
+2,139
+24% +$2.68M ﹤0.01% 2106
2017
Q3 		$12.2M Buy
9,041
+1,601
+22% +$1.69M ﹤0.01% 2082
2017
Q2 		$6.01M Buy
7,440
+861
+13% +$600K ﹤0.01% 2663
2017
Q1 		$4.05M Sell
6,579
-5,327
-45% -$3.24M ﹤0.01% 3080
2016
Q4 		$6.37M Buy
11,906
+7,765
+188% +$3.88M ﹤0.01% 2747
2016
Q3 		$2.14M Buy
4,141
+422
+11% +$199K ﹤0.01% 3447
2016
Q2 		$1.53M Buy
3,719
+164
+5% +$75.1K ﹤0.01% 3646
2016
Q1 		$1.89M Sell
3,555
-791
-18% -$394K ﹤0.01% 3396
2015
Q4 		$3.31M Buy
4,346
+423
+11% +$281K ﹤0.01% 3058
2015
Q3 		$2.15M Buy
3,923
+44
+1% +$26.7K ﹤0.01% 3445
2015
Q2 		$2.28M Sell
3,879
-1,453
-27% -$845K ﹤0.01% 3511
2015
Q1 		$4.18M Sell
5,332
-1,515
-22% -$1.17M ﹤0.01% 2915
2014
Q4 		$4.68M Buy
+6,847
New +$4.41M ﹤0.01% 2784

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Morgan Stanley's KYNB Position: Q2 2026 in Review

Morgan Stanley reduced its Kyntra Bio (KYNB) stake by 0.2% in Q2 2026, selling an estimated $7 and leaving 487 shares worth $3.68K. The position accounts for ﹤0.01% of the portfolio, ranked #7281.

Morgan Stanley first reported a position in KYNB in Q4 2014 and has held it in 47 quarters since. The position peaked at $21.5M in Q2 2018. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

  • Morgan Stanley held 487 shares of Kyntra Bio worth $3.68K as of Q2 2026.
  • Morgan Stanley sold 1 Kyntra Bio share in Q2 2026, an estimated $7.
  • Kyntra Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7281 holding.
  • Morgan Stanley first reported a position in Kyntra Bio in Q4 2014 and has held it in 47 quarters since.
  • Morgan Stanley's Kyntra Bio position peaked at $21.5M in Q2 2018.
  • 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.